Examination of Cardiovascular Outcomes With Alogliptin Versus Standard of Care - EXAMINE


Alogliptin is a novel selective dipeptidyl peptidase 4 (DPP-4) inhibitor that lowers glucose. The current trial sought to study the cardiovascular (CV) safety of alogliptin in patients with type 2 diabetes mellitus (DM2) and recent acute coronary syndrome (ACS).

Contribution to the Literature: The EXAMINE trial showed that alogliptin does not increase the risk of CV events, including heart failure hospitalizations, in patients with diabetes mellitus and recent ACS.